Read about our response to COVID-19

Infectious Diseases

Our company is committed to discovering and developing innovative medicines and vaccines to treat and prevent infectious diseases. We are collaborating with diverse stakeholders to save and improve lives around the world.

For more than 80 years, our company has played a significant role in the discovery and development of novel medicines and vaccines to treat and prevent infectious diseases.

Today, our company is a global leader in infectious disease with a proud heritage, a broad portfolio of vaccines and medicines for HIV, hepatitis C (HCV), Cytomegalovirus (CMV) and antibiotics and antifungals and a pipeline focused on addressing unmet needs in infectious disease.

Infectious diseases are a leading cause of death worldwide, particularly in low- and middle-income countries. According to the World Health Organization (WHO), three of the top ten causes of death worldwide in 2016 were due to infectious diseases, accounting for approximately 5.7 million deaths worldwide. In low-income countries, five of the top ten causes of death were due to infectious diseases.

We apply our research and development resources, expertise and technology to identifying potential products that would address unmet needs in the treatment of infectious diseases. We have multiple programs that span discovery through late-stage development. We are also involved in a number of product-development partnerships and research collaborations to further develop treatments to address infectious diseases, including neglected tropical diseases (NTDs) and tuberculosis (TB).

Beyond our in-house research and engagement with external partners to address infectious diseases, we continue to seek new ways in which we can contribute expertise and resources to these disease areas.

We recognize that new methods and a broader scope of collaborating—with both public and private entities—are critical to supporting continued investment in innovation and to enhancing access. This is true for all diseases, but it is especially true for diseases prevalent in low- and middle-income countries, for which the relevant expertise spans academia, local public health authorities, industry and international agencies. We continue to expand our interactions with these groups to provide relevant expertise and resources.